Public Views of Gene Editing for Babies Depend on How It Would Be Used
By Cary Funk and Meg Hefferon,
Pew Research Center
| 07. 26. 2018
Americans’ views on the appropriateness of changing a baby’s genetic characteristics depend in large part on the intended purpose and on whether or not human embryos would be used in testing these techniques. A majority of Americans support the idea of using gene editing with the goal of delivering direct health benefits for babies, but at the same time, a majority considers the use of such techniques to boost a baby’s intelligence something that takes technology “too far.”
About seven-in-ten Americans (72%) say that changing an unborn baby’s genetic characteristics to treat a serious disease or condition that the baby would have at birth is an appropriate use of medical technology, while 27% say this would be taking technology too far. A somewhat smaller share of Americans say gene editing to reduce a baby’s risk of developing a serious disease or condition over their lifetime is appropriate (60% say this, while 38% say it would be taking medical technology too far). But just 19% of Americans say it would be appropriate to use gene editing to make a baby more...
Related Articles
By Ian Sample, The Guardian | 07.04.2024
Biological models of human embryos that can develop heartbeats, spinal cords and other distinctive features will be governed by a code of practice in Britain to ensure that researchers work on them responsibly.
Made from stem cells, they mimic, to...
By Kevin Davies, Genetic Engineering & Biotechnology News | 06.27.2024
Physician-scientist Matthew Porteus, MD, PhD, has been a mainstay in the genome editing field for more than two decades. He trained at Stanford University Medical School before completing his residency and hematology/oncology fellowship at Boston Children’s Hospital/Dana Farber Cancer Institute...
By Peter Aldhous, Scientific American | 07.02.2024
In June a notice posted on the website of the journal Nature set a new scientific record. It withdrew what is now the most highly cited research paper ever to be retracted.
The study, published in 2002 by Catherine Verfaillie...
By Robert F. Service, Science | 07.04.2024
Image by Ed Uthman from Flickr
Last year, the U.S. Food and Drug Administration (FDA) approved two gene therapy procedures that can treat and, in some cases essentially cure sickle cell disease, a genetic blood disorder that causes pain and...